A Study Of Daratumumab, Low-Dose Oral Dexamethasone and Cyclophosphamide With Or Without Pomalidomide

NCT03215524 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
120
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Canadian Myeloma Research Group